- $495.69m
- $403.02m
Cabaletta Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Autolus Therapeutics rises on agreement with Cabaletta Bio
Brief: Autolus Therapeutics Collaborates With Cabaletta Bio For Autoimmune Disease Cell Therapies
U.S. RESEARCH ROUNDUP-Expensify, NVIDIA, Signature Bank
Cabaletta Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Cabaletta Bio Reports Q3 2022 Financial Results
Cabaletta Bio Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, BlackRock, Domino's Pizza
Brief: Iaso Biotherapeutics And Cabaletta Bio Announce Exclusive License Agreement For Clinically Validated Cd19 Binder
Wells Fargo slashes PT on Cabaletta as autoimmune disorder drug disappoints
Cabaletta falls on disappointing early-stage data on lead drug
Brief: Cabaletta Bio Reports New Interim Data From The Descaartes™ Phase 1 Trial At The 31St EADV Congress
Brief: Eversept Partners Lp Reports 8.24% Passive Stake In Cabaletta Bio As Of August 22
U.S. RESEARCH ROUNDUP-Goodrx Holdings, Nextnav, Olo
Brief: Cabaletta Bio reports Q2 results
U.S. RESEARCH ROUNDUP-Asgn, Equitable Holdings, Verrica Pharmaceuticals
Cabaletta Bio Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cabaletta Bio Reports First Quarter 2022 Financial Results And Provides Business Update
Cabaletta Bio Inc expected to post a loss of 60 cents a share - Earnings Preview